Evidence map›Paper›PMID 40980485›Full record

ReviewInfection prevention in practice2025

Understanding the landscape of carbapenemase-producing organisms (CPOs), and spotlighting opportunities for control in England.

Akaninyene Otu, Jacquelyn McCormick, Katherine L Henderson, Alice Ledda, Danièle Meunier, Bharat Patel, Colin S Brown, Susie Singleton, Emily L Mason, Jasmin Islam and 3 more

Abstract readReview
In one paragraph

Review in Infection prevention in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Akaninyene OtuAntimicrobial Resistance and Healthcare Associated Infections Division, Epidemic and Emerging Infections (EEI) Directorate, UK Health Security Agency, UK.
Jacquelyn McCormickAntimicrobial Resistance and Healthcare Associated Infections Division, Epidemic and Emerging Infections (EEI) Directorate, UK Health Security Agency, UK.
Katherine L HendersonAntimicrobial Resistance and Healthcare Associated Infections Division, Epidemic and Emerging Infections (EEI) Directorate, UK Health Security Agency, UK.
Alice LeddaAntimicrobial Resistance and Healthcare Associated Infections Division, Epidemic and Emerging Infections (EEI) Directorate, UK Health Security Agency, UK.
Danièle MeunierAntimicrobial Resistance and Healthcare Associated Infections Division, Epidemic and Emerging Infections (EEI) Directorate, UK Health Security Agency, UK.
Bharat PatelPublic Health Laboratory London Public Health Microbiology Directorate, Chief Scientific Officer Group, UK Health Security Agency, UK.
Colin S BrownAntimicrobial Resistance and Healthcare Associated Infections Division, Epidemic and Emerging Infections (EEI) Directorate, UK Health Security Agency, UK.
Susie SingletonHealth Equity and Clinical Governance, UK Health Security Agency, UK.
Emily L MasonAntimicrobial Resistance and Healthcare Associated Infections Division, Epidemic and Emerging Infections (EEI) Directorate, UK Health Security Agency, UK.
Jasmin IslamAntimicrobial Resistance and Healthcare Associated Infections Division, Epidemic and Emerging Infections (EEI) Directorate, UK Health Security Agency, UK.
Ginny MooreBiosafety, Air and Water Microbiology Group, UK Health Security Agency, UK.
Katie L HopkinsAntimicrobial Resistance and Healthcare Associated Infections Division, Epidemic and Emerging Infections (EEI) Directorate, UK Health Security Agency, UK.
Dakshika JeyaratnamAntimicrobial Resistance and Healthcare Associated Infections Division, Epidemic and Emerging Infections (EEI) Directorate, UK Health Security Agency, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenemase-producing organisms (CPOs) are an increasing global public health threat for which there are limited effective and affordable therapeutic options. The rise in the incidence of CPO infections and colonisations recorded across the UK and beyond over the last 20 years necessitates a need to review and update strategies for control. It is important to review other countries' frameworks for CPO control and significant CPO outbreaks as these could inform the design of an efficient public health response. Despite many nations reacting to the rise by upscaling public health surveillance of CPOs (and the introduction of mandatory notification in England), improvements in laboratory detection methods, and the linkage of data across jurisdictions, significant challenges remain. For example, though predominantly acquired via cross-transmission between patients in healthcare, there are reports of human infections putatively acquired from CPOs harboured in the natural environment. Given the role of one-health in AMR, this is an important consideration. In this article, we outline some of the CPO control strategies adopted across different countries to give a sense of the global picture, and expand on why, in addition to controls in healthcare, there is a strong need to consider a One-Health approach. We describe the existing framework for CPO control in England and emphasise the importance of an integrated, multi-disciplinary and cross-sectoral strategy for dealing with the multifaceted problem posed by CPO in England.

Indexed as

CarbapenemaseCarbapenemase-producing Enterobacterales (CPE)Carbapenemase-producing organisms (CPOs)EnglandSurveillance

Identifiers

PMID40980485
PMCPMC12445719

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.